streptomycin

Streptomycin (Agrept) is an aminoglycoside antibiotic derived from Streptomyces, a blocker of stretch-activated and mechanically-sensitive ion channels in neurons and cardiomyocytes, with anti-tuberculosis activity. It strongly binds to nucleic acids, interferes with protein synthesis, and can be used to study Mycobacterium tuberculosis infections.

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

Streptomycin sulfate (Phytomycin) is a sulfate salt of streptomycin that is a protein synthesis inhibitor.

Streptomycin BSA is an antigen-adjuvant conjugate formed by coupling Streptomycin with bovine serum albumin (BSA). This conjugation enhances the production of antigen-specific antibodies in vaccine models. Importantly, the conjugate does not affect protein folding or disrupt primary epitopes, and it also enhances cross-presentation and the production of antigen-specific T cells.

Streptomycin KLH is an antigen-adjuvant conjugate of Streptomycin and keyhole limpet hemocyanin (KLH). This conjugation enhances the production of antigen-specific antibodies in vaccine models by linking the antigen with a protein adjuvant. The conjugate does not affect protein folding or disrupt major epitopes, while also enhancing cross-presentation and the generation of antigen-specific T cells.

Streptomycin OVA is an antigen-adjuvant conjugate formed by linking Streptomycin with ovalbumin (OVA). Conjugating the antigen with a protein adjuvant boosts antigen-specific antibody production in vaccine models. This conjugate does not affect protein folding or disrupt major epitopes, while enhancing cross-presentation and the generation of antigen-specific T cells.

Dihydrostreptomycin sulfate (Dihydrostreptomycin sesquisulfate) inhibits protein synthesis by binding to the 30S ribosomal subunit. Dihydrostreptomycin Sulfate is a semi-synthetic aminoglycoside antibiotic with bactericidal properties. This antibiotic is active against most gram-positive and gram-negative organisms and is used in the treatment of tuberculosis and tularemia.

Hydroxystreptomycin is a new antibiotic isolated from Streptomyces Griseocarneus.

Dihydrostreptomycin is an antibiotic.

Streptoniazid is a derivative of streptomycin and serves as an effective antibiotic against tuberculosis.

Streptomyces A-Factor is a microbial hormone found in Streptomyces griseus. A-factor triggers streptomycin biosynthesis and cell differentiation by binding a repressor-type receptor protein (ArpA) and dissociating it from DNA.

Streptobiosamine is a disaccharide component of streptomycin.

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

Ashimycin B is a streptomycin analogue that exhibits broad-spectrum antibacterial activity.

Ashimycin A is an analog of Streptomycin with broad-spectrum antibacterial activity.